Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.64 |
| ▸ | SCN3A | Q9NY46 | 8/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.61 |
| ▸ | SCN4A | P35499 | 1/20 | 0.61 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.61 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.61 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.61 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.61 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | MMP1 | P03956 | 3/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22546620 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL862470 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL24491210 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL310294 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL29685919 | 0.89 | KCNH2 (0.78) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL1093298 | 0.84 | KCNH2 (0.71) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL483308 | 0.84 | KCNH2 (0.71) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL312069 | 0.81 | KCNH2 (0.88) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| Vixotrigine SCHEMBL21930647 | 0.79 | KCNH2 (0.92) | KCNH2SCN3ASCN1ASCN4ASCN7A | |
| SCHEMBL862451 | 0.79 | KCNH2 (0.79) | KCNH2SCN3ASCN1ASCN4ASCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237379-B1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | CONVERGENCE PHARMACEUTICALS (GB) | 2022-04-06 | — | — | EP | disclosed |
| US-10421716-B2 | Process for preparing alpha-carboxamide pyrrolidine derivatives | Convergence Pharmaceuticals Limited (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20170369437-A1 | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | Convergence Pharmaceuticals Limited (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-3237379-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102967-A1 | PROCESS FOR PREPARING ALPHA-CARBOXAMIDE PYRROLIDINE DERIVATIVES | Convergence Pharmaceuticals Limited (GB) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421716-B2 | Process for preparing alpha-carboxamide pyrrolidine derivatives | CPS1, ALDH18A1, PCCA | KCNH2 732/4885SCN3A 2354/4885SCN1A 1528/4885 |
| US-20170369437-A1 | Process for Preparing Alpha-Carboxamide Pyrrolidine Derivatives | CPS1, ALDH18A1, PCCA | KCNH2 732/4885SCN3A 2354/4885SCN1A 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.